CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy

Glioblastoma is the most common and aggressive type of brain tumor with high recurrence and fatality rates. Although various therapeutic strategies have been explored, there is currently no effective treatment for glioblastoma. Recently, the number of immunotherapeutic strategies has been tested for...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Immunol Immunother
Asıl Yazarlar: Hara, Ayaka, Koyama-Nasu, Ryo, Takami, Mariko, Toyoda, Takahide, Aoki, Takahiro, Ihara, Fumie, Kobayashi, Masayoshi, Hirono, Seiichiro, Matsutani, Tomoo, Nakayama, Toshinori, Iwadate, Yasuo, Motohashi, Shinichiro
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Berlin Heidelberg 2020
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8053161/
https://ncbi.nlm.nih.gov/pubmed/33128583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-020-02742-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller